AssetMark Inc’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

AssetMark Inc’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-56	Closed	-$1K	–	1463
2019 Q2	$1K	Buy	56 +10	+22%	+$108	﹤0.01%	1307
2019 Q1	$1K	Sell	46 -52	-53%	-$766	﹤0.01%	1306
2018 Q4	$1K	Sell	98 -23	-19%	-$318	﹤0.01%	1383
2018 Q3	$2K	Sell	121 -10	-8%	-$157	﹤0.01%	1296
2018 Q2	$2K	Hold	131	–	–	﹤0.01%	1294
2018 Q1	$3K	Buy	131 +27	+26%	+$601	﹤0.01%	1238
2017 Q4	$3K	Buy	+104	New	+$2.09K	﹤0.01%	1391

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

AssetMark Inc's CNCE Position: Q3 2019 in Review

AssetMark Inc sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2019, closing a stake of 56 shares — an estimated $1K sold.

AssetMark Inc first reported a position in CNCE in Q4 2017 and held it in 7 quarters. The position peaked at $3K in Q1 2018. 80 funds tracked by Wall St. Rank hold CNCE as of Q3 2019.

AssetMark Inc reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
AssetMark Inc sold 56 Concert Pharmaceuticals, Inc. shares in Q3 2019, an estimated $1K.
AssetMark Inc first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 7 quarters.
AssetMark Inc's Concert Pharmaceuticals, Inc. position peaked at $3K in Q1 2018.
80 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2019.

Based on AssetMark Inc's 13F filing for Q3 2019, filed 13 Nov 2019.